Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas.

[1]  Roman K. Thomas,et al.  Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens , 2011, PloS one.

[2]  A. Gemma,et al.  F1000 highlights , 2010 .

[3]  Richard D. White,et al.  CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung. , 2015, AJR. American journal of roentgenology.

[4]  A. Gemma,et al.  First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[6]  Massimo Bellomi,et al.  CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer , 2015, European Radiology.

[7]  P. Lambin,et al.  Robust Radiomics Feature Quantification Using Semiautomatic Volumetric Segmentation , 2014, PloS one.

[8]  P. Lambin,et al.  CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  Samuel H. Hawkins,et al.  Reproducibility and Prognosis of Quantitative Features Extracted from CT Images. , 2014, Translational oncology.

[10]  M. Tsao,et al.  EGFR mutations and lung cancer. , 2011, Annual review of pathology.

[11]  M. Ladanyi,et al.  Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.

[12]  Jie Tian,et al.  Automated delineation of lung tumors from CT images using a single click ensemble segmentation approach , 2013, Pattern Recognit..

[13]  T. Nagayasu,et al.  Title: Analysis of intra-tumor heterogeneity of EGFR mutations in mixed-type lung adenocarcinoma , 2019 .

[14]  Chun-Ming Tsai,et al.  LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. in’t Veld,et al.  Detection of EGFR-TK Domain-activating Mutations in NSCLC With Generic PCR-based Methods. , 2014, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[16]  Binsheng Zhao,et al.  Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. , 2009, Radiology.

[17]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[18]  K. Miles,et al.  Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival , 2012, European Radiology.

[19]  J. Goo,et al.  Imaging Characteristics of Stage I Non-Small Cell Lung Cancer on CT and FDG-PET: Relationship with Epidermal Growth Factor Receptor Protein Expression Status and Survival , 2013, Korean journal of radiology.

[20]  P. Souquet,et al.  Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18–21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes , 2013, Lung.

[21]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  G. Liu,et al.  Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma , 2014, Journal of thoracic imaging.

[23]  Trygve Randen,et al.  Filtering for Texture Classification: A Comparative Study , 1999, IEEE Trans. Pattern Anal. Mach. Intell..

[24]  Andre Dekker,et al.  Radiomics: the process and the challenges. , 2012, Magnetic resonance imaging.

[25]  Andre Dekker,et al.  A semiautomatic CT-based ensemble segmentation of lung tumors: comparison with oncologists' delineations and with the surgical specimen. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  X. Chen,et al.  Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations , 2015, European Radiology.

[27]  Qinghua Zhou,et al.  Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer , 2013, PloS one.

[28]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[29]  Robert J. Gillies,et al.  Test–Retest Reproducibility Analysis of Lung CT Image Features , 2014, Journal of Digital Imaging.

[30]  L. Tanoue.  Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .

[31]  Charles A Powell,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. , 2011, Proceedings of the American Thoracic Society.

[32]  R. Korn,et al.  Noninvasive Image Texture Analysis Differentiates K-ras Mutation from Pan-Wildtype NSCLC and Is Prognostic , 2014, PloS one.

[33]  Ping Wang,et al.  Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas , 2013, Medical Oncology.

[34]  Gregory J Riely,et al.  Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials , 2009, Clinical Cancer Research.

[35]  Lawrence H. Schwartz,et al.  Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. , 2013, Radiology.

[36]  Kikuya Kato,et al.  Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib , 2008, Cancer science.

[37]  Chaya S Moskowitz,et al.  Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements? , 2014, Lung cancer.

[38]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[39]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[40]  L. Tanoue,et al.  Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .

[41]  Roberto Maroldi,et al.  Texture analysis of advanced non-small cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy , 2013, European Radiology.

[42]  Aaron D Ward,et al.  Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. , 2014, Medical physics.